InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,277.51
(
0.80%
)
US TECH 100
18,064.80
(
0.02%
)
Dow Jones
38,686.32
(
1.51%
)
Brent Oil
81.30
(
0.00%
)
Bitcoin
67,698.44
(
-0.04%
)
Post# of 252009
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 830
Posts 119741
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 195643

Tuesday, 10/13/2015 11:00:00 AM

Tuesday, October 13, 2015 11:00:00 AM

Post# of 252009
PLX monetizes Gaucher drug, Elelyso, by selling worldwide rights—except Brazil—to PFE; PFE also buys 6% equity stake in PLX:

http://finance.yahoo.com/news/protalix-biotherapeutics-sells-share-collaboration-113000945.html

All told, PLX will receive $46M of cash from this transaction ($36M from the divestiture and $10 from the sales of equity), yielding a pro forma 9/30/15 cash balance of about $80M.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up